Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients with stage 3 (unresectable) o...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Queirolo, Paola, Spagnolo, Francesco, Ascierto, Paolo Antonio, Simeone, Ester, Marchetti, Paolo, Scoppola, Alessandro, Del Vecchio, Michele, Di Guardo, Lorenza, Maio, Michele, Di Giacomo, Anna Maria, Antonuzzo, Andrea, Cognetti, Francesco, Ferraresi, Virginia, Ridolfi, Laura, Guidoboni, Massimo, Guida, Michele, Pigozzo, Jacopo, Chiarion Sileni, Vanna
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer US 2014
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023079/
https://ncbi.nlm.nih.gov/pubmed/24532241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1400-y
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg